We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
(+3%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-8.52%
Top 10 Holdings %
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22
Avg Time Held Equity + Options
7.7
quarters
Top 10 Avg Time Held Equity + Options
5.6
quarters
Top 20 Avg Time Held Equity + Options
7.5
quarters
Avg Time Held Equity only
8
quarters
Top 10 Avg Time Held Equity only
5.7
quarters
Top 20 Avg Time Held Equity only
7.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$129M |
| 2 |
Merck
MRK
|
+$76.6M |
| 3 |
Guardant Health
GH
|
+$43.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$87M |
| 2 |
Eli Lilly
LLY
|
+$65.3M |
| 3 |
Apellis Pharmaceuticals
APLS
|
+$61M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.42% |
| 2 | Miscellaneous | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Regeneron Pharmaceuticals
REGN
$77.6B
| $11.4M | 0.23% |
+14,700
| New | +$11.3M |
2026 Q1
0 quarters
|
|
77
Carlsmed
CARL
$399M
| $11.3M | 0.22% |
1,252,600
| – | – |
2025 Q3
2 quarters
|
|
78
Biogen
BIIB
$33.6B
| $11.3M | 0.22% |
+61,600
| New | +$11.4M |
2026 Q1
0 quarters
|
|
79
CALL
Qiagen
QGEN
$9.44B
| $10M | 0.2% |
+250,000
| New | +$11.8M |
2026 Q1
0 quarters
|
|
80
Kiniksa Pharmaceuticals
KNSA
$6.16B
| $8.7M | 0.17% |
180,599
-6,600
| -4% | -$292K |
2025 Q4
1 quarter
|
|
81
Keros Therapeutics
KROS
$222M
| $8.38M | 0.17% |
759,155
-45,057
| -6% | -$696K |
2020 Q2
23 quarters
|
|
82
Gilead Sciences
GILD
$183B
| $8.31M | 0.16% |
+59,600
| New | +$8.35M |
2026 Q1
0 quarters
|
|
83
Heron Therapeutics
HRTX
$74.7M
| $7.85M | 0.16% |
+9,816,940
| New | +$11.4M |
2026 Q1
0 quarters
|
|
84
Avalo Therapeutics
AVTX
$649M
| $7.09M | 0.14% |
475,165
-712,135
| -60% | -$11.1M |
2024 Q3
6 quarters
|
|
85
Tectonic Therapeutic
TECX
$413M
| $7M | 0.14% |
226,600
-348,000
| -61% | -$8.56M |
2025 Q4
1 quarter
|
|
86
Adicet Bio
ACET
$48.5M
| $7M | 0.14% |
1,027,944
| – | – |
2018 Q1
32 quarters
|
|
87
Compass Pathways
CMPS
$1.54B
| $6.36M | 0.13% |
+1,150,646
| New | +$7.74M |
2026 Q1
0 quarters
|
|
88
CALL
Palvella Therapeutics
PVLA
$1.86B
| $6.23M | 0.12% |
+50,000
| New | +$5.22M |
2026 Q1
0 quarters
|
|
89
Pharvaris
PHVS
$2.13B
| $5.8M | 0.12% |
205,400
| – | – |
2025 Q4
1 quarter
|
|
90
ALX Oncology
ALXO
$151M
| $5.75M | 0.11% |
+2,866,256
| New | +$5.46M |
2026 Q1
0 quarters
|
|
91
Artivion
AORT
$1.06B
| $5.53M | 0.11% |
+151,000
| New | +$5.96M |
2026 Q1
0 quarters
|
|
92
InspireMD
NSPR
$24M
| $5.11M | 0.1% |
3,133,405
| – | – |
2023 Q2
11 quarters
|
|
93
Revolution Medicines
RVMD
$40.3B
| $5.06M | 0.1% |
52,000
+26,100
| +101% | +$2.64M |
2025 Q4
1 quarter
|
|
94
ADC Therapeutics
ADCT
$213M
| $4.94M | 0.1% |
1,318,026
-4,504,828
| -77% | -$17.8M |
2024 Q2
7 quarters
|
|
95
Protagonist Therapeutics
PTGX
$8.99B
| $4.44M | 0.09% |
42,100
+20,400
| +94% | +$1.81M |
2025 Q4
1 quarter
|
|
96
Palisade Bio
PALI
$261M
| $4.08M | 0.08% |
2,333,000
+461,580
| +25% | +$839K |
2025 Q4
1 quarter
|
|
97
Alto Neuroscience
ANRO
$880M
| $3.77M | 0.07% |
167,500
+42,500
| +34% | +$788K |
2024 Q4
5 quarters
|
|
98
Savara
SVRA
$994M
| $3.47M | 0.07% |
+635,000
| New | +$3.53M |
2026 Q1
0 quarters
|
|
99
Cullinan Oncology
CGEM
$911M
| $3.45M | 0.07% |
243,006
-27,000
| -10% | -$347K |
2021 Q1
20 quarters
|
|
100
CALL
DELISTED
Soleno Therapeutics
SLNO
| $3.35M | 0.07% |
+100,000
| New | +$3.92M |
2026 Q1
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2026 Portfolio in Review
As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.
- OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
- OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
- OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
- OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
- OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
- OrbiMed opened 26 new positions and closed 22 in Q1 2026.
- OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.